Format
Sort by
Items per page

Send to

Choose Destination

Links from Gene

Items: 1 to 20 of 219

1.

Thrombin-activatable fibrinolysis inhibitor in human abdominal aortic aneurysm disease.

Bridge KI, Bollen L, Zhong J, Hesketh M, Macrae FL, Johnson A, Philippou H, Scott DJ, Gils A, Ariёns RAS.

J Thromb Haemost. 2017 Nov;15(11):2218-2225. doi: 10.1111/jth.13804. Epub 2017 Sep 25.

2.

Suppression of TAFI by siRNA inhibits invasion and migration of breast cancer cells.

Yu C, Luan Y, Wang Z, Zhao J, Xu C.

Mol Med Rep. 2017 Sep;16(3):3469-3474. doi: 10.3892/mmr.2017.7031. Epub 2017 Jul 18.

PMID:
28765963
3.

Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.

Leenaerts D, Aernouts J, Van Der Veken P, Sim Y, Lambeir AM, Hendriks D.

Thromb Haemost. 2017 Jul 26;117(8):1498-1508. doi: 10.1160/TH17-02-0097. Epub 2017 Jul 6.

PMID:
28692110
4.

Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).

Grosso G, Vikerfors A, Woodhams B, Adam M, Bremme K, Holmström M, Ågren A, Eelde A, Bruzelius M, Svenungsson E, Antovic A.

Thromb Res. 2017 Oct;158:168-173. doi: 10.1016/j.thromres.2017.06.028. Epub 2017 Jun 24.

PMID:
28669410
5.

Sex-specific effect of CPB2 Ala147Thr but not Thr325Ile variants on the risk of venous thrombosis: A comprehensive meta-analysis.

Zwingerman N, Medina-Rivera A, Kassam I, Wilson MD, Morange PE, Trégouët DA, Gagnon F.

PLoS One. 2017 May 26;12(5):e0177768. doi: 10.1371/journal.pone.0177768. eCollection 2017.

6.

Thrombin-Activatable Fibrinolysis Inhibitor Gene Polymorphism (TAFI1040C/T) in Women With Recurrent Spontaneous Abortion.

ElDanasori N, Abulata N, Shaheen IA, ElGendy AM, El-Khayat W.

Clin Appl Thromb Hemost. 2018 Apr;24(3):532-535. doi: 10.1177/1076029617695485. Epub 2017 Feb 22.

PMID:
28301909
7.

Imaging analyses of coagulation-dependent initiation of fibrinolysis on activated platelets and its modification by thrombin-activatable fibrinolysis inhibitor.

Brzoska T, Suzuki Y, Sano H, Suzuki S, Tomczyk M, Tanaka H, Urano T.

Thromb Haemost. 2017 Apr 3;117(4):682-690. doi: 10.1160/TH16-09-0722. Epub 2017 Feb 2.

PMID:
28150854
8.

Activated thrombin-activatable fibrinolysis inhibitor attenuates the angiogenic potential of endothelial cells: potential relevance to the breast tumour microenvironment.

Bazzi ZA, Balun J, Cavallo-Medved D, Porter LA, Boffa MB.

Clin Exp Metastasis. 2017 Feb;34(2):155-169. doi: 10.1007/s10585-017-9837-y. Epub 2017 Jan 25.

PMID:
28124276
9.

Thrombin activatable fibrinolysis inhibitor as a bleeding predictor in liver transplantation: a pilot observational study.

Nedel WL, Rodrigues Filho EM, Pasqualotto AC.

Rev Bras Ter Intensiva. 2016 Jun;28(2):161-6. doi: 10.5935/0103-507X.20160031. English, Portuguese.

10.

Elucidation of the molecular mechanisms of two nanobodies that inhibit thrombin-activatable fibrinolysis inhibitor activation and activated thrombin-activatable fibrinolysis inhibitor activity.

Zhou X, Weeks SD, Ameloot P, Callewaert N, Strelkov SV, Declerck PJ.

J Thromb Haemost. 2016 Aug;14(8):1629-38. doi: 10.1111/jth.13381. Epub 2016 Jul 27.

11.

Meta-analysis of TAFI polymorphisms and risk of cardiovascular and cerebrovascular diseases.

Wang SW, Zhang HH, Dong CY, Sun HH.

Genet Mol Res. 2016 Apr 4;15(2). doi: 10.4238/gmr.15026718.

12.

Thrombin-Activatable Fibrinolysis Inhibitor in Chronic Thromboembolic Pulmonary Hypertension.

Yaoita N, Satoh K, Satoh T, Sugimura K, Tatebe S, Yamamoto S, Aoki T, Miura M, Miyata S, Kawamura T, Horiuchi H, Fukumoto Y, Shimokawa H.

Arterioscler Thromb Vasc Biol. 2016 Jun;36(6):1293-301. doi: 10.1161/ATVBAHA.115.306845. Epub 2016 Apr 21.

PMID:
27102961
13.

Molecular Mechanism Underlying the Suppression of CPB2 Expression Caused by Persistent Hepatitis C Virus RNA Replication.

Sejima H, Satoh S, Dansako H, Honda M, Kaneko S, Ikeda M, Kato N.

Acta Med Okayama. 2016;70(2):75-88.

14.

Association between thrombin-activatable fibrinolysis inhibitor gene polymorphisms and venous thrombosis risk: a meta-analysis.

Wang W, Ma H, Lu L, Sun G, Liu D, Zhou Y, Tong Y, Lu Z.

Blood Coagul Fibrinolysis. 2016 Jun;27(4):419-30. doi: 10.1097/MBC.0000000000000475.

PMID:
26656901
15.

Selective modulation of thrombin-activatable fibrinolysis inhibitor (TAFI) activation by thrombin or the thrombin-thrombomodulin complex using TAFI-derived peptides.

Plug T, Marquart JA, Marx PF, Meijers JC.

J Thromb Haemost. 2015 Nov;13(11):2093-101. doi: 10.1111/jth.13133. Epub 2015 Sep 30.

16.

Plasma levels of carboxypeptidase U (CPU, CPB2 or TAFIa) are elevated in patients with acute myocardial infarction.

Leenaerts D, Bosmans JM, van der Veken P, Sim Y, Lambeir AM, Hendriks D.

J Thromb Haemost. 2015 Dec;13(12):2227-32. doi: 10.1111/jth.13135. Epub 2015 Nov 12.

17.

Lack of TAFI increases brain damage and microparticle generation after thrombolytic therapy in ischemic stroke.

Orbe J, Alexandru N, Roncal C, Belzunce M, Bibiot P, Rodriguez JA, Meijers JC, Georgescu A, Paramo JA.

Thromb Res. 2015 Aug;136(2):445-50. doi: 10.1016/j.thromres.2015.06.010. Epub 2015 Jun 11.

PMID:
26118976
18.

Impact of genetic polymorphisms in thrombin activatable fibrinolysis inhibitor (TAFI) on venous thrombosis disease: A meta-analysis.

Qian K, Xu J, Wan H, Fu F, Lu J, Lin Z, Liu Z, Liu H.

Gene. 2015 Sep 15;569(2):173-81. doi: 10.1016/j.gene.2015.06.014. Epub 2015 Jun 10. Review.

PMID:
26071134
19.

Generation of a stable thrombin-activatable fibrinolysis inhibitor deletion mutant exerting full carboxypeptidase activity without activation.

Zhou X, Declerck PJ.

J Thromb Haemost. 2015 Jun;13(6):1084-9. doi: 10.1111/jth.12894. Epub 2015 Apr 6.

20.

Effect of single nucleotide polymorphism in thrombin-activatable fibrinolysis inhibitor on the risk of diabetic macrovascular disease.

Zheng C, Li X, Kong C, Ke S, Peng C, Cui T, Gao M, Zhou Y, Guo W, Huang L, Petersen RB, Huang K.

Blood Coagul Fibrinolysis. 2015 Mar;26(2):185-90. doi: 10.1097/MBC.0000000000000216.

PMID:
25396763

Supplemental Content

Support Center